The estimated Net Worth of Mark Jeffrey De Long is at least $3.15 Million dollars as of 12 August 2024. Mark Long owns over 5,201 units of Apellis Pharmaceuticals Inc stock worth over $2,316,752 and over the last 3 years Mark sold APLS stock worth over $833,006.
Sign up
Mark Long APLS stock SEC Form 4 insiders trading
Mark has made over 19 trades of the Apellis Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Mark exercised 5,201 units of APLS stock worth $72,034 on 12 August 2024.
The largest trade Mark's ever made was exercising 10,000 units of Apellis Pharmaceuticals Inc stock on 4 August 2022 worth over $155,200. On average, Mark trades about 2,732 units every 41 days since 2021. As of 12 August 2024 Mark still owns at least 60,395 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Mark Long stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Mark Long's mailing address?
Mark's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.
Insiders trading at Apellis Pharmaceuticals Inc
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois, and Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
What does Apellis Pharmaceuticals Inc do?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
What does Apellis Pharmaceuticals Inc's logo look like?
Complete history of Mark Long stock trades at Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc executives and stock owners
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Cedric Francois,
President, Chief Executive Officer, Co-Founder, Director -
Lukas Scheibler,
Chief Innovation Officer -
Federico Grossi,
Chief Medical Officer -
Thomas Lackner,
Senior Vice President, Head of Europe -
Pascal Deschatelets,
Co-Founder, Chief Operating Officer -
Timothy Sullivan,
Chief Financial Officer, Treasurer -
Dr. Cedric Francois,
Co-Founder, Pres, CEO & Director -
Timothy E. Sullivan,
Chief Financial Officer -
Dr. Pascal Deschatelets Ph.D.,
Co-Founder & Chief Scientific Officer -
Adam J. Townsend,
Chief Commercial Officer -
Gerald Chan,
Independent Chairman of the Board -
Stephanie O'Brien,
Independent Director -
Alec Machiels,
Independent Director -
A. Sinclair Dunlop,
Independent Director -
Alec Machiels J.D., MBA,
Co-Founder & Independent Director -
Sam Martin,
IR Contact Officer -
Paul Fonteyne,
Independent Director -
Adam Townsend,
Chief Commercial Officer -
David Watson,
General Counsel, Vice President of Corporate Development -
Nicole Perry,
Vice President - Finance -
Victoria Brown,
Senior Vice President, Program Team Lead – Systemic Chronic -
David O. Watson,
Gen. Counsel -
Meredith Kaya,
Sr. VP, Investor Relations & Strategic Fin. -
James G. Chopas CPA,
VP, Corp. Controller & Chief Accounting Officer -
Dr. Lukas Scheibler M.D., Ph.D.,
Chief Innovation Officer -
Karen Lewis,
Chief People Officer -
Nur Nicholson,
Chief Technical Operations Officer -
Dr. Federico Grossi M.D., Ph.D.,
Co-Founder & Chief Medical Officer -
Nur Nicholson,
Chief Technical Officer -
Karen Lewis,
Chief People Officer -
Venture Investments Ltd Mor...,
10% owner -
Lucia Celona,
See Remarks -
Ahmad Sadr,
See Remarks -
Jeffrey Eisele,
Chief Development Officer -
Mark Jeffrey De Long,
Chief Business & Strat Officer -
James George Chopas,
VP/Chief Accounting Officer -
Caroline Baumal,
Chief Medical Officer